Evidence map›Paper›PMID 36403561›Full record

ArticleTuberculosis (Edinburgh, Scotland)2022

Evaluation of three alternatives cost-effective culture media for Mycobacterium tuberculosis detection and drug susceptibility determination using the microscopic observation drug susceptibility (MODS) assay.

Jhojailith Rodriguez, Roberto Alcántara, Joseline Rodríguez, Johnny Vargas, Elisa Roncal, Ricardo Antiparra, Robert H Gilman, Louis Grandjean, David Moore, Mirko Zimic and 1 more

Open access · greenAbstract read
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. A simplified pyrazinamidase test forJournal of clinical microbiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Jhojailith RodriguezLaboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru.
Roberto AlcántaraLaboratory of Biomolecules, Faculty of Health Sciences, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, 15023, Peru.
Joseline RodríguezLaboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru.
Johnny VargasInstituto Peruano de Energía Nuclear (IPEN), Lima, 15076, Peru.
Elisa RoncalLaboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru.
Ricardo AntiparraLaboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru.
Robert H GilmanJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, United States.
Louis GrandjeanDepartment of Infection, Immunity, and Inflammation, Institute of Child Health, London, WC1N 1EH, UK.
David MooreTB Centre, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Mirko ZimicLaboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru.
Patricia SheenLaboratorio de Bioinformática, Biología Molecular y Desarrollos Tecnológicos, Laboratorios de Investigación y Desarrollo. Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, 15102, Peru. Electronic address: patricia.sheen@upch.pe.
Universidad Peruana Cayetano Heredia · PEInstitute of Infection and Immunity · CAInstituto Peruano de Energía NuclearJohns Hopkins University · USLondon School of Hygiene & Tropical Medicine · GBPeruvian University of Applied Sciences · PE

Funding

Using the Mycobacterium tuberculosis Genome to Predict Tuberculosis Pathology, Drug Resistance Acquisition and Identify Community Transmission SitesR01AI146338 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GILMAN, ROBERT H · 2020 to 2024
$3.3M
NIAID NIH HHS R01 AI146338
6 · The paper itself

Abstract

Tuberculosis phenotypic detection assays are commonly used in low-resource countries. Therefore, reliable detection methods are crucial for early diagnosis and treatment. The microscopic observation drug susceptibility (MODS) assay is a culture-based test to detect Mycobacterium tuberculosis and characterize drug resistance in 7-10 days directly from sputum. The use of MODS is limited by the availability of supplies necessary for preparing the enriched culture. In this study, we evaluated three dry culture media that are easier to produce and cheaper than the standard one used in MODS [1]: an unsterilized powder-based mixed (Boldú et al., 2007) [2], a sterile-lyophilized medium, and (Sengstake et al., 2017) [3] an irradiated powder-based mixed. Mycobacterial growth and drug susceptibility were evaluated for rifampin, isoniazid, and pyrazinamide (PZA). The alternative cultures were evaluated using 282 sputum samples with positive acid-fast smears. No significant differences were observed in the positivity test rates. The positivity time showed high correlations (Rho) of 0.925, 0.889, and 0.866 between each of the three alternative media and the standard. Susceptibility testing for MDR and PZA showed an excellent concordance of 1 compared to the reference test. These results demonstrate that dry culture media are appropriate and advantageous for use in MODS in low-resource settings.

Indexed as

Mycobacterium tuberculosisTuberculosis, Lymph NodeTuberculosis, Multidrug-ResistantAntitubercular AgentsCost-Benefit AnalysisCulture MediaHumansMicrobial Sensitivity TestsPowdersSensitivity and SpecificityAntitubercular AgentsCulture MediaPowdersCulture mediaDiagnosisDrug susceptibility testMODSTuberculosis

Identifiers

PMID36403561
PMCPMC10022417
OpenAlexW4308980334

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.